Quick Telecast
Expect News First

Moderna says its kids COVID-19 vaccine is effective, seeks approval from FDA

0 41



The many parents anxiously waiting for a COVID-19 vaccine for their young kids got one step closer to their vax goal Wednesday with the announcement of a candidate readying for FDA approval.

Moderna announced that its lower-dose coronavirus vaccine is effective for children ages 6 months to under 6 years old. The Cambridge-based biotech pioneering mRNA vaccines also said it will seek approval for this vax from the Food and Drug Administration.

“We believe these latest results from the KidCOVE study are good news for parents of children under 6 years of age,” Moderna CEO Stéphane Bancel said. “We now have clinical data on the performance of our vaccine from infants six months of age through older adults.

“Given the need for a vaccine against COVID-19 in infants and young children, we are working with the U.S. FDA and regulators globally to submit these data as soon as possible,” Bancel added.

KidCOVE is a randomized, placebo-controlled study to evaluate the safety, tolerability and immune response of two vax doses given to healthy children 28 days apart. Overall, Moderna has enrolled about 11,700 pediatric participants in the U.S. and Canada into the trial, including about 4,200 children ages 2 to under 6 years and about 2,500 children ages 6 months to under 2 years.

In both age groups, the vax was generally well tolerated — similar to the tolerability as in children age 6 to under 12, in adolescents age 12 to 17 and in adults. The majority of adverse events were mild or moderate and were more frequently reported after the second dose.

Fever rates among vaccine recipients were along the same lines as with other commonly used and recommended pediatric vaccines, Moderna said. Also, no new safety concerns were identified in either age group.

No deaths, no myocarditis or pericarditis and no multisystem inflammatory syndrome in children were reported.



The many parents anxiously waiting for a COVID-19 vaccine for their young kids got one step closer to their vax goal Wednesday with the announcement of a candidate readying for FDA approval.

Moderna announced that its lower-dose coronavirus vaccine is effective for children ages 6 months to under 6 years old. The Cambridge-based biotech pioneering mRNA vaccines also said it will seek approval for this vax from the Food and Drug Administration.

“We believe these latest results from the KidCOVE study are good news for parents of children under 6 years of age,” Moderna CEO Stéphane Bancel said. “We now have clinical data on the performance of our vaccine from infants six months of age through older adults.

“Given the need for a vaccine against COVID-19 in infants and young children, we are working with the U.S. FDA and regulators globally to submit these data as soon as possible,” Bancel added.

KidCOVE is a randomized, placebo-controlled study to evaluate the safety, tolerability and immune response of two vax doses given to healthy children 28 days apart. Overall, Moderna has enrolled about 11,700 pediatric participants in the U.S. and Canada into the trial, including about 4,200 children ages 2 to under 6 years and about 2,500 children ages 6 months to under 2 years.

In both age groups, the vax was generally well tolerated — similar to the tolerability as in children age 6 to under 12, in adolescents age 12 to 17 and in adults. The majority of adverse events were mild or moderate and were more frequently reported after the second dose.

Fever rates among vaccine recipients were along the same lines as with other commonly used and recommended pediatric vaccines, Moderna said. Also, no new safety concerns were identified in either age group.

No deaths, no myocarditis or pericarditis and no multisystem inflammatory syndrome in children were reported.

FOLLOW US ON GOOGLE NEWS

Read original article here

Denial of responsibility! Quick Telecast is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a comment
buy kamagra buy kamagra online
Ads Blocker Image Powered by Code Help Pro

Ads Blocker Detected!!!

We have detected that you are using extensions to block ads. Please support us by disabling these ads blocker.

Powered By
Best Wordpress Adblock Detecting Plugin | CHP Adblock